A patent review of PRMT5 inhibitors to treat cancer (2018 - present)

References

• Antonysamy S, Bonday Z, Campbell RM, et al. Crystal structure of the human PRMT5:MEP50 complex. Proc Natl Acad Sci U S A. 2012 Oct;109(44):17960–17965.
   PubMed Web of Science ®Google Scholar
• Yang Y, Bedford MT. Protein arginine methyltransferases and cancer. Nat Rev Cancer. 2013 Jan;13(1):37–50.
   PubMed Web of Science ®Google Scholar
• Morettin A, Baldwin RM, Côté J. Arginine methyltransferases as novel therapeutic targets for breast cancer. Mutagenesis. 2015 Mar;30(2):177–189.
   PubMed Web of Science ®Google Scholar
• Sun L, Wang M, Lv Z, et al. Structural insights into protein arginine symmetric dimethylation by PRMT5. Proc Natl Acad Sci U S A. 2011 Dec;108(51):20538–20543.
   PubMed Web of Science ®Google Scholar
• Schapira M, Ferreira de Freitas R. Structural biology and chemistry of protein arginine methyltransferases. Medchemcomm. 2014 Dec;5(12):1779–1788.
   PubMed Web of Science ®Google Scholar
• Zhang X, Cheng X. Structure of the predominant protein arginine methyltransferase PRMT1 and analysis of its binding to substrate peptides. Structure. 2003 May;11(5):509–520.
   PubMed Web of Science ®Google Scholar
• Ancelin K, Lange UC, Hajkova P, et al. Blimp1 associates with Prmt5 and directs histone arginine methylation in mouse germ cells. Nat Cell Biol. 2006 Jun;8(6):623–630.
   PubMed Web of Science ®Google Scholar
• Guderian G, Peter C, Wiesner J, et al. RioK1, a new interactor of protein arginine methyltransferase 5 (PRMT5), competes with pICln for binding and modulates PRMT5 complex composition and substrate specificity. J Biol Chem. 2011 Jan;286(3):969–977.
   Web of Science ®Google Scholar
• Friesen WJ, Paushkin S, Wyce A, et al. The methylosome, a 20S complex containing JBP1 and pICln, produces dimethylarginine-modified Sm proteins. Mol Cell Biol. 2001 Dec;21(24):8289–8300.
   PubMed Web of Science ®Google Scholar
• Le Guezennec X, Vermeulen M, Brinkman AB, et al. MBD2/NuRD and MBD3/NuRD, two distinct complexes with different biochemical and functional properties. Mol Cell Biol. 2006 Feb;26(3):843–851.
   PubMed Web of Science ®Google Scholar
• Friesen WJ, Wyce A, Paushkin S, et al. A novel WD repeat protein component of the methylosome binds Sm proteins. J Biol Chem. 2002 Mar;277(10):8243–8247.
   PubMed Web of Science ®Google Scholar
• Krause CD, Yang ZH, Kim YS, et al. Protein arginine methyltransferases: evolution and assessment of their pharmacological and therapeutic potential. Pharmacol Ther. 2007 Jan;113(1):50–87.
   PubMed Web of Science ®Google Scholar
• Harris DP, Bandyopadhyay S, Maxwell TJ, et al. Tumor necrosis factor (TNF)-α induction of CXCL10 in endothelial cells requires protein arginine methyltransferase 5 (PRMT5)-mediated nuclear factor (NF)-κB p65 methylation. J Biol Chem. 2014 May;289(22):15328–15339.
   PubMed Web of Science ®Google Scholar
• Wei H, Wang B, Miyagi M, et al. PRMT5 dimethylates R30 of the p65 subunit to activate NF-κB. Proc Natl Acad Sci U S A. 2013 Aug;110(33):13516–13521.
   PubMed Web of Science ®Google Scholar
• Zheng S, Moehlenbrink J, Lu YC, et al. Arginine methylation-dependent reader-writer interplay governs growth control by E2F-1. Mol Cell. 2013 Oct;52(1):37–51.
   PubMed Web of Science ®Google Scholar
• Jansson M, Durant ST, Cho EC, et al. Arginine methylation regulates the p53 response. Nat Cell Biol. 2008 Dec;10(12):1431–1439.
   PubMed Web of Science ®Google Scholar
• Scoumanne A, Zhang J, Chen X. PRMT5 is required for cell-cycle progression and p53 tumor suppressor function. Nucleic Acids Res. 2009 Aug;37(15):4965–4976.
   PubMed Web of Science ®Google Scholar
• Xu X, Hoang S, Mayo MW, et al. Application of machine learning methods to histone methylation ChIP-Seq data reveals H4R3me2 globally represses gene expression. BMC Bioinformatics. 2010 Jul;11(1):396.
   PubMedGoogle Scholar
• Majumder S, Alinari L, Roy S, et al. Methylation of histone H3 and H4 by PRMT5 regulates ribosomal RNA gene transcription. J Cell Biochem. 2010 Feb;109(3):553–563.
   PubMed Web of Science ®Google Scholar
• Yue M, Li Q, Zhang Y, et al. Histone H4R3 methylation catalyzed by SKB1/PRMT5 is required for maintaining shoot apical meristem. PLoS One. 2013;8(12):e83258.
   PubMed Web of Science ®Google Scholar
• Migliori V, Müller J, Phalke S, et al. Symmetric dimethylation of H3R2 is a newly identified histone mark that supports euchromatin maintenance. Nat Struct Mol Biol. 2012 Jan;19(2):136–144.
   PubMed Web of Science ®Google Scholar
• Pal S, Baiocchi RA, Byrd JC, et al. Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma. The EMBO Journal. 2007 Aug;26(15):3558–3569.
   PubMed Web of Science ®Google Scholar
• Chung J, Karkhanis V, Baiocchi RA, et al. Protein arginine methyltransferase 5 (PRMT5) promotes survival of lymphoma cells via activation of WNT/β-catenin and AKT/GSK3β proliferative signaling. J Biol Chem. 2019 May;294(19):7692–7710.
   PubMed Web of Science ®Google Scholar
• Gullà A, Hideshima T, Bianchi G, et al. Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma. Leukemia. 2018 Apr;32(4):996–1002.
   PubMed Web of Science ®Google Scholar
• Zhang B, Dong S, Zhu R, et al. Targeting protein arginine methyltransferase 5 inhibits colorectal cancer growth by decreasing arginine methylation of eIF4E and FGFR3. Oncotarget. 2015 Sep;6(26):22799–22811.
   PubMedGoogle Scholar
• Shailesh H, Siveen KS, Sif S. Protein arginine methyltransferase 5 (PRMT5) activates WNT/β-catenin signalling in breast cancer cells via epigenetic silencing of DKK1 and DKK3. J Cell Mol Med. 2021 Feb;25(3):1583–1600.
   PubMed Web of Science ®Google Scholar
• Yang F, Wang J, Ren HY, et al. Proliferative role of TRAF4 in breast cancer by upregulating PRMT5 nuclear expression. Tumour Biol. 2015 Aug;36(8):5901–5911.
   PubMedGoogle Scholar
• Jing P, Zhao N, Ye M, et al. Protein arginine methyltransferase 5 promotes lung cancer metastasis via the epigenetic regulation of miR-99 family/FGFR3 signaling. Cancer Lett. 2018 Jul;427:38–48.
   PubMed Web of Science ®Google Scholar
• Li Z, Zhang J, Liu X, et al. The LINC01138 drives malignancies via activating arginine methyltransferase 5 in hepatocellular carcinoma. Nat Commun. 2018 Apr;9(1):1572.
   PubMedGoogle Scholar
• Jia Z, Yue F, Chen X, et al. Protein arginine methyltransferase PRMT5 regulates fatty acid metabolism and lipid droplet biogenesis in white adipose tissues. Adv Sci (Weinh). 2020 Dec;7(23):2002602.
   PubMedGoogle Scholar
• LeBlanc SE, Konda S, Wu Q, et al. Protein arginine methyltransferase 5 (Prmt5) promotes gene expression of peroxisome proliferator-activated receptor γ2 (PPARγ2) and its target genes during adipogenesis. Mol Endocrinol. 2012 Apr;26(4):583–597.
   PubMedGoogle Scholar
• Muhammad AB, Xing B, Liu C, et al. Menin and PRMT5 suppress GLP1 receptor transcript and PKA-mediated phosphorylation of FOXO1 and CREB. Am J Physiol Endocrinol Metab. 2017 Aug;313(2):E148–e166.
   PubMed Web of Science ®Google Scholar
• Tsai WW, Niessen S, Goebel N, et al. PRMT5 modulates the metabolic response to fasting signals. Proc Natl Acad Sci U S A. 2013 May;110(22):8870–8875.
   PubMed Web of Science ®Google Scholar
• Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. Lancet. 2017 Jun;389(10085):2239–2251.
   PubMed Web of Science ®Google Scholar
• Cai S, Liu R, Wang P, et al. PRMT5 prevents cardiomyocyte hypertrophy via symmetric dimethylating HoxA9 and repressing HoxA9 expression. Front Pharmacol. 2020;11:600627.
   PubMed Web of Science ®Google Scholar
• Chen M, Yi B, Sun J. Inhibition of cardiomyocyte hypertrophy by protein arginine methyltransferase 5. J Biol Chem. 2014 Aug;289(35):24325–24335.
   PubMed Web of Science ®Google Scholar
• Harris DP, Chandrasekharan UM, Bandyopadhyay S, et al. PRMT5-mediated methylation of NF-κB p65 at Arg174 is required for endothelial CXCL11 gene induction in response to TNF-α and IFN-γ costimulation. PLoS One. 2016;11(2):e0148905.
   PubMed Web of Science ®Google Scholar
• Quan X, Yue W, Luo Y, et al. The protein arginine methyltransferase PRMT5 regulates Aβ-induced toxicity in human cells and Caenorhabditis elegans models of Alzheimer’s disease. J Neurochem. 2015 Sep;134(5):969–977.
   PubMed Web of Science ®Google Scholar
• Ross CA, Aylward EH, Wild EJ, et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol. 2014 Apr;10(4):204–216.
   PubMed Web of Science ®Google Scholar
• Ratovitski T, Arbez N, Stewart JC, et al. PRMT5- mediated symmetric arginine dimethylation is attenuated by mutant huntingtin and is impaired in Huntington’s disease (HD). Cell Cycle. 2015;14(11):1716–1729.
   PubMed Web of Science ®Google Scholar
• Zhan X, Stamova B, Sharp FR. Lipopolysaccharide associates with amyloid plaques, neurons and oligodendrocytes in Alzheimer’s disease brain: a review. Front Aging Neurosci. 2018;10:42.
   PubMed Web of Science ®Google Scholar
• Feustel K, Falchook GS. Protein arginine methyltransferase 5 (PRMT5) inhibitors in oncology clinical trials: a review. J Immunother Precis Oncol. 2022 Aug;5(3):58–67.
   PubMedGoogle Scholar
• Wang Y, Hu W, Yuan Y. Protein arginine methyltransferase 5 (PRMT5) as an anticancer target and its inhibitor discovery. J Med Chem. 2018 Nov;61(21):9429–9441.
   PubMed Web of Science ®Google Scholar
• Chan-Penebre E, Kuplast KG, Majer CR, et al. A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models. Nat Chem Biol. 2015 Jun;11(6):432–437.
   PubMed Web of Science ®Google Scholar
• Epizyme Inc. Arginine methyltransferase inhibitors and uses thereof. WO2016022605. 2016.
   Google Scholar
• Siu LL, Rasco DW, Vinay SP, et al. METEOR-1: a phase I study of GSK3326595, a first-in-class protein arginine methyltransferase 5 (PRMT5) inhibitor, in advanced solid tumours. Ann Oncol. 2019;30:v159.
   PubMed Web of Science ®Google Scholar
• Gerhart SV, Kellner WA, Thompson C, et al. Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing. Sci Rep. 2018 Jun;8(1):9711.
   PubMedGoogle Scholar
• Angel Villalona-Calero AP M, Maki RG, O’Neil B, et al. Design and rationale of a phase 1 dose-escalation study of AMG 193, a methylthioadenosine (MTA)-cooperative PRMT5 inhibitor, in patients with advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors. J Clin Oncol. 2022;TPS3167–TPS3167.
   Web of Science ®Google Scholar
• Marjon K, Cameron MJ, Quang P, et al. MTAP deletions in cancer create vulnerability to targeting of the MAT2A/PRMT5/RIOK1 Axis. Cell Rep. 2016 Apr;15(3):574–587.
   PubMed Web of Science ®Google Scholar
• JNJ-64619178. NCI drug dictionary, national institutes of health–national cancer institute. 2023. Comprehensive Cancer Information - NCI (date:10-02-2023)
   Google Scholar
• Tao H, Yan X, Zhu K, et al. Discovery of novel PRMT5 inhibitors by virtual screening and biological evaluations. Chem Pharm Bull. 2019;67(4):382–388.
   PubMed Web of Science ®Google Scholar
• Jensen-Pergakes K, Tatlock J, Maegley KA, et al. SAM-competitive PRMT5 Inhibitor PF-06939999 demonstrates antitumor activity in splicing dysregulated NSCLC with decreased liability of drug resistance. Mol Cancer Ther. 2022 Jan;21(1):3–15.
   PubMed Web of Science ®Google Scholar
• Tango therapeutics announces clearance of TNG908 IND by FDA and recent pipeline progress updates. 2022.
   Google Scholar
• Prelude therapeutics announces third quarter 2022 financial results and provides business update. 2022.
   Google Scholar
• Egloff S. CDK9 keeps RNA polymerase II on track. Cell Mol Life Sci. 2021 Jul;78(14):5543–5567.
   PubMed Web of Science ®Google Scholar
• Smith CR, Aranda R, Bobinski TP, et al. Fragment-based discovery of MRTX1719, a synthetic lethal inhibitor of the PRMT5*MTA complex for the treatment of MTAP-deleted cancers. J Med Chem. 2022 Feb;65(3):1749–1766.
   PubMed Web of Science ®Google Scholar
• Asberry AM, Cai X, Deng X, et al. Discovery and Biological Characterization of PRMT5:MEP50 Protein-Protein Interaction Inhibitors. J Med Chem. 2022 Oct;65(20):13793–13812.
   PubMed Web of Science ®Google Scholar
• Amgen Inc. Tricyclic-amide-bicyclic PRMT5 inhibitors. WO2022169948. 2022.
   Google Scholar
• Angex pharmaceutial, Inc. Heterocyclic compounds as PRMT5 inhhibitors. WO2020243178A1. 2020.
   Google Scholar
• Angex pharmaceutial, Inc. Heterocyclic compounds as PRMT5 inhhibitors. WO2019112719A1. 2019.
   Google Scholar
• Aurigene discovery tech limited. Imidazolidin-2-one compounds as PRMT5 modulators. WO2019180628. 2019.
   Google Scholar
• Aurigene Discovery Tech Ltd. Substituted imidazolidin-2-one derivatives as PRMT5 inhibitors. WO2019180631A1. 2019.
   Google Scholar
• Aurigene Discovery Tech Ltd. Substituted imidazolidin-2-one deri vatives as PRMT5 inhibitors. CN112105609A. 2020.
   Google Scholar
• Bayer AG Thiazole compounds useful as PRMT5 inhibitors. WO2019002074A1. 2019.
   Google Scholar
• Bayer Aktiengesellschaft Thiazole compounds useful as PRMT5 inhibitors. US20200123147A1. 2020.
   Google Scholar
• Shoda T, Ohoka N, Tsuji G, et al. Targeted protein degradation by chimeric compounds using hydrophobic E3 ligands and adamantane moiety. Pharmaceuticals (Basel). 2020 Feb;13(3):34.
   PubMedGoogle Scholar
• Janssen Pharmaceutica NV. Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors. CN107922413A. 2018.
   Google Scholar
• Janssen Pharmaceutica NV. Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors. WO2017032840A1. 2017.
   Google Scholar
• Janssen Pharmaceutica NV. Novel Spirobicyclic analogue. WO2019110734A1. 2019.
   Google Scholar
• Janssen Pharmaceutica NV. Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as PRMT5 inhibitors. WO2018065365A1. 2018.
   Google Scholar
• Lupin limited substituted bicyclic heterocyclic compounds as PRMT5 inhibitors. CN111712498A. 2020.
   Google Scholar
• Lupin limited PRMT5 inhibitors. CN114026094A. 2022.
   Google Scholar
• Lupin limited substituted nucleoside analogs as PRMT5 inhibitors. WO2021111322A1. 2021.
   Google Scholar
• Lupin limited pharmaceutical combination of PRMT5 inhibitor. CN114599361A. 2022.
   Google Scholar
• Lupin limited pharmaceutical combination of PRMT5 inhibitor. WO2021079302A1. 2021.
   Google Scholar
• Merck sharp & Dohme PRMT5 inhibitors. WO2019094311A1. 2019.
   Google Scholar
• Merck Sharp & Dohme PRMT5 inhibitors. WO2019094312A1. 2019.
   Google Scholar
• Merck Sharp & Dohme PRMT5 inhibitors. WO2021126728A1. 2021.
   Google Scholar
• Merck Sharp & Dohme PRMT5 inhibitors. WO2021126729A1. 2021.
   Google Scholar
• Merck Sharp & Dohme PRMT5 inhibitors. WO2020033285. 2020.
   Google Scholar
• Merck Sharp & Dohme PRMT5 inhibitors. WO2020033288. 2020.
   Google Scholar
• MIRATI THERAPEUTICS INC. MTA-cooperative PRMT5 inbihitors. WO2021050915A1. 2021.
   Google Scholar
• MIRATI THERAPEUTICS INC. Aminopyridine-based MTA-cooperative PRMT5 inbihitors. WO2023278564A1. 2023.
   Google Scholar
• PRELUDE THERAPEUTICS INC. Selective inhibitors of protein arginine methyl transferase 5 (PRMTS). WO2018085833. 2018.
   Google Scholar
• PRELUDE THERAPEUTICS INC. Selective inhibitors of protein arginine methyl transferase 5 (PRMTS). WO2018152501. 2018.
   Google Scholar
• PRELUDE THERAPEUTICS INC. Selective inhibitors of protein arginine methyltransferase 5 (PRMTS). WO2018152548. 2018.
   Google Scholar
• PRELUDE THERAPEUTICS INC. Selective inhibitors of protein arginine methyl transferase 5 (PRMTS). WO2019178368. 2019.
   Google Scholar
• PRELUDE THERAPEUTICS INC. Selective inhibitors of protein arginine methyl transferase 5 (PRMTS). WO2018160855. 2018.
   Google Scholar
• Jiangsu Simcere Pharm Co Ltd. Tetrahydroisoquinoline compounds and use thereof. WO2022002142A1. 2022.
   Google Scholar
• Nanjing Sanhome Pharmaceutical Res And Development Co Ltd. Tricyclic compound as prmt5 inhibitor and application thereof. CN112645946A. 2021.
   Google Scholar
• Zhengzhou University Arginine methyltransferase 5 small molecule inhibitor and preparation method and use thereof. CN111592522. 2020.
   Google Scholar
• Shanghai Apeiron Biotechnology Co Ltd. Used as a nucleoside analogue of PRMT5 inhibitors. CN113234079. 2021.
   Google Scholar
• California Inst of Tech PRMT5 inhibitors and their uses. CN114127072. 2020.
   Google Scholar
• Indian University research technology small molecule protein arginine methyltransferase 5 (PRMT5) inhibitors and therapeutics. WO2018081451. 2018.
   Google Scholar
• Gao H, Sun X, Rao Y. PROTAC technology: opportunities and challenges. ACS Med Chem Lett. 2020 Mar;11(3):237–240.
   PubMed Web of Science ®Google Scholar
• Sun X, Gao H, Yang Y, et al. PROTACs: great opportunities for academia and industry. Signal Transduct Target Ther. 2019;4:64.
   PubMed Web of Science ®Google Scholar
• Lai AC, Crews CM. Induced protein degradation: an emerging drug discovery paradigm. Nat Rev Drug Discov. 2017 Feb;16(2):101–114.
   PubMed Web of Science ®Google Scholar
• Schapira M, Calabrese MF, Bullock AN, et al. Targeted protein degradation: expanding the toolbox. Nat Rev Drug Discov. 2019 Dec;18(12):949–963.
   PubMed Web of Science ®Google Scholar
• Shen Y, Gao G, Yu X, et al. Discovery of first-in-class protein arginine methyltransferase 5 (PRMT5) degraders. J Med Chem. 2020 Sep;63(17):9977–9989.
   PubMed Web of Science ®Google Scholar
• McKinney DC, McMillan BJ, Ranaghan MJ, et al. Discovery of a first-in-class inhibitor of the PRMT5-substrate adaptor interaction. J Med Chem. 2021 Aug;64(15):11148–11168.
   PubMed Web of Science ®Google Scholar